Kinney Drugs Scales Back AI Phone Assistant After Complaints
The pharmacy chain is reverting to traditional phone systems for incoming calls after customers reported dosage errors and missed notifications.
Regional pharmacy chain retreats from AI automation
Kinney Drugs has significantly scaled back deployment of its AI phone assistant following hundreds of customer complaints about system failures that included wrong dosage information, incoherent communications, and missed prescription notifications.
The pharmacy chain launched the AI assistant, named Burt after company founder Burton Kinney, in May 2026 to handle patient communications about prescriptions and refills. Within months, the technology proved problematic enough that the company is now reverting to traditional touch-tone phone systems for all incoming patient calls.
Why it matters
This rollback illustrates a critical gap between technical compliance and user experience in healthcare AI deployments. Even when systems meet regulatory standards like HIPAA, poor execution can erode patient trust and create safety risks. For healthcare organizations evaluating AI automation, the case demonstrates that privacy compliance alone doesn't guarantee successful implementation — the technology must also deliver reliable, accurate service in high-stakes clinical contexts.
What went wrong
According to VTDigger, which first reported the story, customers experienced multiple failure modes with the AI system. The assistant delivered incoherent responses during calls, provided incorrect medication dosage information, and failed to properly notify patients about prescription status.
Kinney Drugs President John Marraffa acknowledged the implementation failures directly. "One thing I want to point out is getting privacy and security right does not mean we got the experience right. We did not, and we own that," Marraffa stated.
Beyond functional problems, customers raised concerns about whether their personal health information could be exposed through the AI platform — a particularly sensitive issue given the nature of pharmacy data.
Limited AI role going forward
The company will maintain Burt for a narrow set of outbound communications, specifically prescription refill text messages. However, patients must actively opt in to receive these automated messages.
For incoming calls, Kinney is returning to its previous system that relies on traditional phone menus rather than conversational AI.
Marraffa emphasized that the AI system is HIPAA compliant and clarified that Burt is not built on open-source technology and does not generate or manipulate patient data independently.
Broader implications for healthcare AI
The Kinney Drugs experience reflects broader challenges facing healthcare organizations as they attempt to automate patient-facing services. While AI promises efficiency gains, deployment in clinical settings requires exceptional accuracy and reliability standards that current technology doesn't always meet.
The incident also highlights how quickly patient trust can erode when automated systems fail in healthcare contexts, where errors can have direct health consequences.
Details of the rollback were first reported by WCAX and VTDigger.
This is an original analysis by the Omega editorial team. Source reporting: AI Watch.
Want systems like this working for your business?
Book a Call
